Research & Education

12th Webinar: IASLC Lung Cancer Grand Rounds Series - Best of 2014 Lung Cancer Research and High Priority NCI Lung Cancer Trials

Tuesday, January 20, 2015 - Recording Available

 

   

Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Associate Director for Translational Research
Director, Thoracic Oncology Research Program
Yale Comprehensive Cancer Center
Yale School of Medicine

Ramaswamy Govindan, MD - Program Chair
Co-Director, Section of Medical Oncology
Professor of Medicine
Division of Oncology
Washington University School of Medicine

IASLC is holding a LIVE WEBINAR featuring Dr. Roy Herbst. During this live webinar, Dr. Herbst will identify and discuss the key developments and advances reported over the past year. The program will emphasize:

Name of Reviewer(s): 

              

Dr. Fred Hirsch- Speakers Bureau/Advisory Board: Astrazeneca, Genentech, BMS, Lilly and Abbvie.

Name of Planner(s): 

 

     Deb Whippen-Nothing to Disclose

Name of Activity: 

 

Best of 2014 Lung Cancer Research and High Priority NCI Lung Cancer Trials

Date of Activity:

 

01/20/2015

Faculty/Speaker(s):

 

Ramaswamy Govindan, MD -Moderator-Pfizer: Advisory Board, Celgene: Advisory Board, AztraZeneca: Advisory Board, INC Research: Consulting, AbbVie: Consulting, Advisory Board and Honorarium, MSK: Advisory Board.

Roy S. Herbst, MD, PhD-Speaker -Disclosures:

Dr Herbst is part of Scientific Advisory Board for: Biothere, Diatech, Kolltan, N of 1, Novarx

He is also does Consulting for: Eli Lilly, Genentech/Roche and Merck.

Type of Activity: 

 Live Course

  Internet Live Course (Webinar)XXXX

 Internet Enduring Material

Are there Commercial Supporters for this activity?

     YES

If yes, please list: Program sponsored/grant by: Bristol-Myers Squibb, Celgene and Genentech

Following the presentation, there will be ample time for discussion and a question/answer session. Attendees will be able to submit questions and comments to Dr. Herbst via internet chat.

After attending this program, participants will:

  • Articulate key developments in clinical research most likely to impact patient care

  • Describe evolving standards of care in the multidisciplinary management of thoracic malignancies

  • Identify and discuss the major clinical trials now underway in lung cancer

  • Evaluate treatment and management options in the personalized medicine paradigm

DOWNLOAD RECORDING

IASLC Policy on Financial Relationships and Conflicts of Interest

IASLC Invited Speaker Honoraria Policy

IASLC Commercial Support Agreement

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.  Participants who complete a pre-and post-test along with an evaluation will receive 1 AMA PRA Category 1 CreditTM for each completed webinar.  

Financial/Commercial Relationships DISCLOSURES 

A Conflict of Interest (COI) is created and exists when individuals in a position to control the content of CME, or their spouses/partners, that have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells, or distributes health care goods or services consumed by, or used, on patients that benefits the individual in any financial amount and therefore, may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected. 

 This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

IASLC CME assures that the planners/reviewers/authors/faculty/moderators/peer reviewers et. al. conflicts of interest  were identified, reviewed and resolved from all individuals involved in the development  or able to influence and control the content of this CME activity; IASLC CME assures that disclosure is given prior to an educational activity being delivered to learners.  Any individual who failed or refused to disclose relevant financial relationships was disqualified from this CME activity and removed from any of IASLC CME activity presentation.

All commercial relationships and conflicts of interest that are identified are thoroughly vetted by IASLC Ethics Committee, CME Subcommittee, and Independent reviewer. COI will be evaluated by the Board of Directors of the IASLC for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. IASLC CME is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.

 

CREDIT STATEMENT

IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IASLC CME designates this Internet Live Course activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

GOAL & PURPOSE

  • Evolving standards of care
  • The most relevant clinical research results likely to impact patient care in the near future
  • Advances in the multidisciplinary management of patients with lung cancer
  • Major NCI clinical trials currently underway

TARGET AUDIENCE

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

DISCLAMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Thank you for your participation.

Location Local time Time zone UTC offset
Los Angeles (U.S.A. - California) Tuesday, January 20, 2015 at 6:00:00 PM PST UTC-8 hours
Denver (U.S.A. - Colorado) Tuesday, January 20, 2015 at 7:00:00 PM MST UTC-7 hours
Chicago (U.S.A. - Illinois) Tuesday, January 20, 2015 at 8:00:00 PM CST UTC-6 hours
New York (U.S.A. - New York) Tuesday, January 20, 2015 at 9:00:00 PM EST UTC-5 hours
São Paulo (Brazil - São Paulo) Midnight between Tuesday, January 20, 2015 and Wednesday, January 21, 2015 BRST UTC-2 hours
Paris (France) Wednesday, January 21, 2015 at 3:00:00 AM CET UTC+1 hour
Hong Kong (Hong Kong) Wednesday, January 21, 2015 at 10:00:00 AM HKT UTC+8 hours
Tokyo (Japan) Wednesday, January 21, 2015 at 11:00:00 AM JST UTC+9 hours
Corresponding UTC (GMT) Wednesday, January 21, 2015 at 02:00:00